Daily Roundup

GQG.ASX BSA.ASX HCW.ASX COH.ASX AVH.ASX

Strong Earnings and Approvals Highlight Busy Day for Australian Firms

GQG Partners kicked off the day with a bang, reporting stellar 2024 results. The asset manager saw net flows surge to a whopping $20.2 billion, nearly doubling the previous year. This fueled a 26.9% jump in funds under management to $153 billion and drove impressive 47% and 50% increases in revenue and operating income, respectively.

Cochlear also had reason to celebrate, with a 7% rise in half-year underlying profit to $205.5 million. The hearing implant specialist saw solid demand, with cochlear implant revenue up 12% and acoustic implant revenue soaring 21%. However, services revenue dipped 13% due to lower upgrade rates.

The news wasn't all positive, though. HealthCo Healthcare and Wellness REIT reported a 30% plunge in revenue and a 208% surge in losses for the first half of 2025. The REIT did manage to maintain its 4.2 cent per unit distribution.

Meanwhile, BSA Ltd surprised the market by temporarily pausing trading in its securities, though the reason for the pause was not specified.

Rounding out the day, AVITA Medical delivered a strong quarter, with commercial revenue up 30% and an impressive 87.6% gross margin. The regenerative medicine company also scored key FDA approvals for new products Cohealyx and RECELL GO mini.

Overall, it was a mixed bag for Australian firms, with some impressive financial results offset by a trading halt and weaker REIT performance. Investors will be closely watching to see how these companies navigate the road ahead.